## Supplementary Materials

Annual risk of hepatitis E virus infection and seroreversion: insights from a serological cohort in Sitakunda, Bangladesh

Amy Dighe<sup>1</sup>, Ashraful Islam Khan<sup>2</sup>, Taufiqur Rahman Bhuiyan<sup>2</sup>, Md Taufiqul Islam<sup>2</sup>, Zahid Hasan Khan<sup>2</sup>, Ishtiakul Islam Khan<sup>2</sup>, Juan Dent Hulse<sup>1</sup>, Shakeel Ahmed<sup>3</sup>, Mamunur Rashid<sup>3</sup>, Md Zakir Hossain<sup>3</sup>, Rumana Rashid<sup>3</sup>, Sonia Hegde<sup>1</sup>, Emily S Gurley<sup>†1</sup>, Firdausi Qadri<sup>†2</sup>, Andrew S Azman<sup>†1,4,5</sup>

- 1. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- 2. icddr,b, Dhaka, Bangladesh.
- 3. Bangladesh Institute of Tropical and Infectious Diseases, Chattogram, Bangladesh
- 4. Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland
- 5. Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland

\*Corresponding author: <u>adighe1@jhmi.edu</u>, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St,

Baltimore, MD 21205

†Equal contributions

## Contents

Figure S1. Location of sampled sites.

## Catalytic model solutions

Table S1. Number of individuals and households sampled during the study.

Figure S2. Semivariogram of the semivariance in household level seroprevalence.

**Table S2**: Demographic characteristics of study participants.

Figure S3. Annual seroconversion and seroreversion rates by age.

Figure S4. The changes in the optical density (od) to cut-off ratios for samples taken at baseline and at follow-up

Table S3. The difference in expected log predicted density (ELPD) compared to the preferred catalytic model.

Figure S5. Predicted seroprevalence by age.

Figure S6. The expected log-predictive density (ELPD) for different age thresholds for changing risk of infection

Figure S7. A comparison of the age-stratified seroprevalence by round.

 Table S4. A comparison of annual risk of infection estimates when using age-stratified seroprevalence at baseline

 versus at follow-up.

Figure S8. A comparison of posterior estimates of the annual risk of infection when we fit the rate of seroreversion,

 $\rho$ , simultaneously with the annual risk of infection, to age-stratified cross-sectional seroprevalence data.



**Figure S1.** Location of sampled sites. Sitakunda (green) within Chattogram district, Bangladesh. Sample sites are shown on the inset map, with households sampled in both rounds represented in blue and households sampled at baseline only before being lost to follow-up represented in red.

## Catalytic model solutions

1) Model 1 - without seroreversion:



a. Assuming a constant force of infection,  $\lambda$ , with age and time, the proportion seropositive, *p*, at age *a* is:

$$p(a) = 1 - e^{-\lambda a}$$

And so, the proportion seropositive, *p*, in the age class spanning  $a_1$ - $a_2$  is given by:

$$p(\overline{a_1 \to a_2}) = \frac{1}{a_2 - a_1} \left( a_2 - a_1 + \frac{1}{\lambda} (e^{-\lambda a_2} - e^{-\lambda a_1}) \right)$$

- b. Assuming the force of infection can be different in children  $\leq a_0$  years old and adults  $>a_0$ 
  - i. When a  $\leq a_0$  the proportion seropositive at age a is:

$$p(a) = 1 - e^{-\lambda_C a}$$

And so, the proportion seropositive in the age class spanning  $a_1$ - $a_2$  where both are  $\leq a_0$  is:

$$p(\overline{a_1 \to a_2}) = \frac{1}{a_2 - a_1} \left( a_2 - a_1 + \frac{1}{\lambda_c} (e^{-\lambda_c a_2} - e^{-\lambda_c a_1}) \right)$$

ii. For adults, where age  $a > a_0$ , the proportion seropositive at age a is:

$$p(a) = 1 - e^{-\lambda_C a_0 - \lambda_A (a - a_0)}$$

And so, the proportion seropositive in the age class spanning  $a_1$ - $a_2$  where both are > $a_0$  is:

$$p(\overline{a_1 \to a_2}) = \frac{1}{a_2 - a_1} \left( a_2 - a_1 + \frac{1}{\lambda_A} \left( e^{-(\lambda_C a_0 + \lambda_A (a_2 - a_0))} - e^{-(\lambda_C a_0 + \lambda_A (a_1 - a_0))} \right) \right)$$

2) Model 2 - with seroreversion:



a. Assuming a constant force of infection,  $\lambda$ , with age and time, the proportion seropositive, *p*, at age *a* is:

$$p(a) = \frac{\lambda}{\lambda + \sigma} \left( 1 - e^{-(\lambda + \sigma)a} \right)$$

And so, the proportion seropositive, *p*, in the age class spanning  $a_1$ - $a_2$  is given below, where  $\sigma$  is the annual rate of seroreversion.

$$p(\overline{a_1 \to a_2}) = \frac{1}{a_2 - a_1} \left( \frac{\lambda}{\lambda + \sigma} \left( (a_2 - a_1) + \frac{1}{\lambda + \sigma} (e^{-(\lambda + \sigma)a_2} - e^{-(\lambda + \sigma)a_1}) \right) \right)$$

- b. Assuming the force of infection and the annual rate of seroreversion vary with age. The force of infection changes at age  $a_{\lambda}$  and the annual rate of seroreversion changes at age  $a_{\sigma}$ . We assume  $a_{\lambda} > a_{\sigma}$ .
  - i. When  $a \le a_{\sigma}$ : the proportion seropositive at age a is:

$$p_1(a) = \frac{\lambda_I}{\lambda_I + \sigma_I} (1 - e^{-(\lambda_I + \sigma_I)a})$$

And so, when we solve for the age class spanning  $a_1$ - $a_2$ , where both are  $\leq a_{\sigma}$ , we get:

$$p_1(\overline{a_1 \to a_2}) = \frac{1}{a_2 - a_1} \left( \frac{\lambda_I}{\lambda_I + \sigma_I} \left( (a_2 - a_1) + \frac{1}{\lambda_I + \sigma_I} (e^{-(\lambda_I + \sigma_I)a_2}) - e^{-(\lambda_I + \sigma_I)a_1}) \right) \right)$$

ii. When  $a_{\sigma} < a \le a_{\lambda}$ 

$$p_2(a) = 1 - \left[ \left( 1 - p_1(a_\sigma) \right) * \left( 1 - \frac{\lambda_I}{\lambda_I + \sigma_{II}} \left( 1 - e^{-(\lambda_I + \sigma_{II})(a - a_\sigma)} \right) \right) \right]$$

And so, when we solve for the age class  $a_1$ - $a_2$ , where both are  $>a_{\sigma}$  and  $\leq a_{\lambda}$ , we get:

$$p_{2}(\overline{a_{1} \rightarrow a_{2}}) = \frac{1}{a_{2} - a_{1}} \Big[ (a_{2} - a_{1}) - (1 - p_{1}(a_{\sigma})) \\ * \Big( (a_{2} - a_{1}) * \Big( 1 - \frac{\lambda_{I}}{\lambda_{I} + \sigma_{II}} \Big) - \frac{1}{\lambda_{I} + \sigma_{II}} * \frac{\lambda_{I}}{\lambda_{I} + \sigma_{II}} * e^{(\lambda_{I} + \sigma_{II})a_{\sigma}} * (e^{-(\lambda_{I} + \sigma_{II})a_{2}} \\ - e^{-(\lambda_{I} + \sigma_{II})a_{1}}) \Big] \Big]$$

iii. When  $a > a_{\lambda}$ 

$$p_{3}(a) = 1 - \left[ \left( 1 - p_{2}(a_{\lambda}) \right) * \left( 1 - \frac{\lambda_{II}}{\lambda_{II} + \sigma_{II}} (1 - e^{-(\lambda_{II} + \sigma_{II})(a - a_{\lambda})}) \right) \right]$$

And so, when we solve for the age class  $a_1$ - $a_2$ , where both are  $>a_{\sigma}$  and  $\leq a_{\lambda}$ , we get:

$$p_{3}(\overline{a_{1} \rightarrow a_{2}}) = \frac{1}{a_{2} - a_{1}} \Big[ (a_{2} - a_{1}) - (1 - p_{2}(a_{\lambda})) \\ * \Big( (a_{2} - a_{1}) * \Big( 1 - \frac{\lambda_{II}}{\lambda_{II} + \sigma_{II}} \Big) - \frac{1}{\lambda_{II} + \sigma_{II}} * \frac{\lambda_{II}}{\lambda_{II} + \sigma_{II}} * e^{(\lambda_{II} + \sigma_{II})a_{\lambda}} * (e^{-(\lambda_{II} + \sigma_{II})a_{\lambda}} \\ - e^{-(\lambda_{II} + \sigma_{II})a_{1}}) \Big] \Big]$$

Table S1. Numbe	r of individuals and	l households sam	npled during	the study
-----------------	----------------------	------------------	--------------	-----------

	R1: Mar-Jun 2021		R2: Jan-Feb 2022		Both rounds	
	individuals	households	individuals	households	individuals	households
Participated	2337	580	2038	494	1993	494
Blood sampled	2308	580	1986	493	1862	493
HEV result available	2301	580	1986	493	1856	492
Excluding borderline	2294	579	1978	492	1846	491
results						

Note that one household enrolled at round 1 had split into two new households by r2, but this table still counts them as a single household followed up.



*Figure S2: A*. The semivariogram showing the semivariance in household level seroprevalence plotted against the distance between households. *B.* The distribution of distance between sampled households.

**Table S2**: demographic characteristics of study participants, shown overall, split by sex and for the community within the cluster of high seroprevalence in southeast Sitakunda.

	Characteristic		all tested n (%)	male n (%)	female n (%)	cluster* n (%)
	Sex	Female	1232 (54%)	NA	1232 (100%)	65 (47%)
		Male	1062 (46%)	1062 (100%)	NA	72 (53%)
	Age in years	<5	93 (4%)	53 (5%)	40 (3%)	6 (4%)
		5-14	436 (19%)	213 (20%)	223 (18%)	23 (17%)
		15-39	1029 (45%)	444 (42%)	585 (47%)	73 (53%)
		40-100	736 (32%)	352 (33%)	384 (31%)	35 (26%)
	Occupation	Homeworker	844 (37%)	78 (7%)	766 (62%)	47 (34%)
		Business*	502 (22%)	438 (41%)	64 (5%)	42 (31%)
		Farmer	80 (3%)	79 (7%)	1 (0%)	6 (4%)
		Student	666 (29%)	345 (32%)	321 (26%)	30 (22%)
		Child	96 (4%)	51 (5%)	45 (4%)	4 (3%)
		None	71 (3%)	41 (4%)	30 (2%)	2 (1%)
		Other	34 (1%)	29 (3%)	5 (0%)	6 (4%)
vel		NA	1 (0%)	1 (0%)	NA	NA
ual le	Travel: time since last	> 1 year	2140 (93%)	982 (92%)	1158 (94%)	129 (94%)
ndivid	leaving the village	1 month - 1 year	112 (5%)	59 (6%)	53 (4%)	5 (4%)
-		1 week - 1 month	24 (1%)	10 (1%)	14 (1%)	3 (2%)
		< 1 week	18 (1%)	11 (1%)	7 (1%)	NA
	Primary drinking water	No	2199 (96%)	1019 (96%)	1180 (96%)	108 (79%)
	at least once in the past	Yes	93 (4%)	41 (4%)	52 (4%)	28 (20%)
	month	NA	2 (0%)	2 (0%)	NA	1 (1%)
		improved	2287 (100%)	1058 (100%)	1229 (100%)	136 (99%)
	Water source category	unimproved	3 (0%)	1 (0%)	2 (0%)	NA
		NA	4 (0%)	3 (0%)	1 (0%)	1 (1%)
		No	1981 (86%)	910 (86%)	1071 (87%)	105 (77%)
	Use of piped water in the past week	Yes	309 (14%)	149 (14%)	160 (13%)	31 (23%)
		NA	4 (0%)	3 (0%)	1 (0%)	1 (1%)
	Lise of tubewell in the	No	466 (20%)	225 (21%)	241 (20%)	40 (29%)
	past week	Yes	1824 (80%)	834 (79%)	990 (80%)	96 (70%)

		NA	4 (0%)	3 (0%)	1 (0%)	1 (1%)
	Use of water from a	No	2109 (92%)	971 (91%)	1138 (92%)	128 (93%)
	public tap/standpipe in	Yes	181 (8%)	88 (8%)	93 (8%)	8 (6%)
	the past week	NA	4 (0%)	3 (0%)	1 (0%)	1 (1%)
	Self-reported ever having	No	1829 (80%)	842 (79%)	987 (80%)	105 (77%)
	had acute jaundice	Yes	56 (2%)	33 (3%)	23 (2%)	1 (1%)
		NA	409 (18%)	187 (18%)	222 (18%)	31 (23%)
		Single house	1509 (66%)	712 (67%)	797 (65%)	123 (90%)
		Several separate structures	311 (14%)	137 (13%)	174 (14%)	14 (10%)
	Type of dwelling	Flat in a multi-story building	210 (9%)	94 (9%)	116 (9%)	NA
		Flat in a single-story building	166 (7%)	74 (7%)	92 (7%)	NA
level		Room in a larger dwelling	98 (4%)	45 (4%)	53 (4%)	NA
blode		<10,000 BDT	367 (16%)	166 (16%)	201 (16%)	31 (24%)
House	Household income	>10,000 BDT	1927 (84%)	896 (84%)	1031 (84%)	105 (76%)
		Improved private	1736 (76%)	800 (75%)	936 (76%)	87 (64%)
	Sanitation facility category	Improved shared	543 (24%)	255 (24%)	288 (23%)	50 (36%)
		Unimproved	15 (1%)	7 (1%)	8 (1%)	NA
	Keens mammalian	No	1631 (71%)	756 (71%)	875 (71%)	74 (54%)
	livestock in the	Yes	658 (29%)	305 (29%)	353 (29%)	63 (46%)
	household	NA	5 (0%)	1 (0%)	4 (0%)	NA

\*the subset of households located in the high seroprevalence cluster in south-east Sitakunda



*Figure S3.* Annual seroconversion and seroreversion rates by age. *A.* the annual seroconversion rate per capita by age shown with 95%Cls, accounting for household sampling. *B.* The annual seroreversion rate per capita by age shown with 95%Cls, accounting for household sampling.



*Figure S4*. The changes in the optical density (od) to cut-off ratios for samples taken at baseline and at follow-up from **A**. individuals who seroreverted during the study, **B**. individuals who seroconverted during the study, and **C**. Individuals who were classed as seropositive at both time points. The area below dashed red lines shows values classed as seronegative, and the area above dashed red lines shows values classed as seropositive, whilst the values between the dashed red lines are borderline and have been excluded.

**Table S3.** The difference in expected log predicted density (ELPD) compared to the preferred catalytic model of seroconversion, as estimated using Leave One Out Cross-validation



**Figure S5.** Predicted seroprevalence by age. Predicted seroprevalence by age is shown in blue for each model, overlaid on the age-stratified baseline seroprevalence measured in our dataset and plotted at the mid-point of each age class. Blue transparent ribbon shows 95%Credible intervals and pink error bars show 95%Confidence intervals for the data.



*Figure S6.* The expected log-predictive density (ELPD) for different age thresholds for changing risk of infection. The EPLD as estimated using LOO-CV is shown with standard error bars for **A.** Model 1 in which we assume antibodies last for life (no seroreversion), **B.** Model 2 assuming instead that the rate of seroreversion that we measured empirically in our cohort, and **C**. Model 3 in which the annual risk of infection and the rate of seroreversion are both simultaneously fitted to cross-sectional seroprevalence data.



Figure S7. A comparison of the age-stratified seroprevalence by round.

Table S4. A comparison of annual risk of infection estimates when using age-stratified seroprevalence at baselin	е
versus at follow-up.	

Round	Annual risk of infection (mean and 95% Crl)		
	<30 year olds	>30 year olds	
Baseline	1.1% (0.8-1.4%)	4.5% (3.7-5.4%)	
Follow-up	0.9% (0.7, 1.2%)	4.1% (3.3-5.1%)	



**Figure S8.** A comparison of posterior estimates of the annual risk of infection when we fit the rate of seroreversion,  $\rho$ , simultaneously with the annual risk of infection, to age-stratified cross-sectional seroprevalence data. The results are shown alongside Models 1 and 2 (presented in the main text), along with the estimates of the annual risk of infection from observed seroconversion events captured in our longitudinal serostatus data (points with bars representing 95%CIs.